• Featured Product
  • KD/KO Validated

B4GALT7 Polyclonal antibody

B4GALT7 Polyclonal Antibody for ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, ELISA

Conjugate

Unconjugated

Cat no : 10535-1-AP

Synonyms

B4GAL T7, B4GALT7, Beta 1,4 GalTase 7, beta4Gal T7, XGALT 1, XGALT1, XGPT, XGPT1



Tested Applications

Recommended dilution

ApplicationDilution
Sample-dependent, check data in validation data gallery

Product Information

10535-1-AP targets B4GALT7 in WB, ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Cited Reactivityhuman
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen B4GALT7 fusion protein Ag0793 相同性解析による交差性が予測される生物種
Full Name xylosylprotein beta 1,4-galactosyltransferase, polypeptide 7 (galactosyltransferase I)
Calculated molecular weight 37 kDa
Observed molecular weight 37 kDa
GenBank accession numberBC007317
Gene symbol B4GALT7
Gene ID (NCBI) 11285
RRIDAB_2274457
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

B4GALT7 (Beta-1,4-galactosyltransferase 7), also known as galactosyltransferase I, is involved in the formation of proteoglycans which are components of the extracellular matrix in connective tissues (PubMed: 10438455). The reduced activity of B4GALT7 results in delayed wound repair, altered migration, adhesion and contractility of patient fibroblasts (PMID: 16583246, PMID: 18158310). Mutations in B4GALT7 that also result in Spondylodysplastic (PMID: 24755949, PMID: 12417421).

Protocols

Product Specific Protocols
WB protocol for B4GALT7 antibody 10535-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanWB

Eur J Hum Genet

Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease.

Authors - Dziedzic Dariusz D
  • KD Validated